Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives
Autor: | Qing Zhou, Yi-Long Wu, Yi-Chen Zhang |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Lung Neoplasms 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Epidermal growth factor receptor Lung cancer Protein Kinase Inhibitors EGFR inhibitors biology business.industry Disease progression medicine.disease Third generation respiratory tract diseases ErbB Receptors 030104 developmental biology Tolerability Drug Resistance Neoplasm 030220 oncology & carcinogenesis biology.protein Non small cell business DISEASE RELAPSE |
Zdroj: | Cancer Letters. 459:240-247 |
ISSN: | 0304-3835 |
Popis: | Discovery of activating mutations in epidermal growth factor receptor (EGFR) as a predictive biomarker for first-generation EGFR tyrosine kinase inhibitors (TKIs) has initiated an era of precision oncology for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). Despite the robust efficacy of first- and second-generation EGFR TKIs, disease relapse is inevitable. EGFR T790M mutation is the predominant cause of disease relapse and third-generation, irreversible EGFR inhibitors designed for targeting EGFR T790M and activating mutations have demonstrated promising clinical activity and tolerability. Unfortunately, disease progression inevitably occurs and heterogenous resistance mechanisms have been reported with limited subsequent treatment strategies available. Till now, treatment approaches for patients progressed from third-generation EGFR TKIs have not been clearly established. In this review, we summarize the recent findings in resistance mechanisms to third-generation EGFR TKIs and emerging treatment approaches for EGFR-mutant patients after resistance to third-generation EGFR TKIs. We further discuss clinical challenges and future perspectives for management of EGFR-mutant patients resistant to third-generation EGFR TKIs. |
Databáze: | OpenAIRE |
Externí odkaz: |